Neomorph and AbbVie have entered into a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.

Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to $1.64 billion in aggregate option fees and milestones, as well as tiered royalties on net sales.